Clinical trials: Blood Pressure, High
Hypertension, Pulmonary
Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
- Trial name
- NCT00185315
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- 16 sites in Belgium, France and 5 more
- Volunteers
- 71 people
- Sponsor
- Bayer
Hypertension, Dyslipidemias
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers
a study to investigate the pharmacokinetic characteristics and safety/tolerability according to formulations of CKD-386 in healthy male volunteers
- Trial name
- NCT03920579
- Testing
- CKD-386 formulation 1, CKD-386 formulation 2, D326, D337 and D013
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Systolic
A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients
This is a double-blind, sham-controlled clinical trial assessing the effectiveness of personalized isometric handgrip device therapy.
- Trial name
- NCT04467879
- Testing
- Zona Plus Device, Control Device
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Zona Health, Inc
Pulmonary Arterial Hypertension
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423202
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension, Renal Dysfunction
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis).
- Trial name
- NCT01131845
- Testing
- UT-15C SR (treprostinil diethanolamine)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04024072
- Testing
- Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Padagis LLC
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Hypertension
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.
- Trial name
- NCT00785512
- Testing
- Nebivolol
- Where
- 26 sites in United States
- Volunteers
- 207 people
- Sponsor
- Forest Laboratories
Hypertension
Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension
Study to assess the blood pressure lowering effects of two doses of telmisartan over a four-week treatment period; to determine potentially effective doses for pediatric patients for future studies; to assess the safety and…
- Trial name
- NCT02242344
- Testing
- Telmisartan
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
Normal Tension Glaucoma
Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma
Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma
- Trial name
- NCT03106532
- Testing
- PHP-201 0.25% ophthalmic solution, PHP-201 0.5% ophthalmic solution
- Where
- South Korea
- Volunteers
- 119 people
- Sponsor
- pH Pharma
Open Angle Glaucoma (OAG)
Safety and Performance Study of the CyPass System Applier Model 241
This is a retrospective chart review of cases in which the CyPass Micro-Stent was implanted using the Model 241 Applier. The objective of this study is to characterize and evaluate the safety of the Model 241 Applier when used…
- Trial name
- RePASS (NCT02228577)
- Where
- Germany
- Volunteers
- 172 people
- Sponsor
- Transcend Medical, Inc.
Hypertension
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
Primary objective: To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria.
- Trial name
- NCT00334581
- Testing
- Irbesartan
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Sanofi
Primary Open Angle Glaucoma, Ocular Hypertension
A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a phase 3 study to confirm the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04863365
- Testing
- PHP-201 ophthalmic solution
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- pH Pharma
Hypertension
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
The aim of this study is to compare the effect of treatment with telmisartan on patients in whom the systolic BP is approximately 12 weeks after starting treatment under control for the first time between patients with isolated…
- Trial name
- TELSYS (NCT02242877)
- Testing
- Telmisartan, Telmisartan combined with hydrochlorothiazide
- Volunteers
- 3,320 people
- Sponsor
- Boehringer Ingelheim
Glaucoma
Glaucoma Evaluation With the P200TE
Images captured on the P200TE device on glaucoma patients
- Trial name
- NCT06305481
- Testing
- P200TE
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Optos, PLC
Neovascular Glaucoma
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.
- Trial name
- NCT04519619
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 480 people
- Sponsor
- Bayer
Hypertension, Hyperlipidemias
To Evaluate Safety and Effectiveness of RovatitanTab.
To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia
- Trial name
- NCT04398771
- Testing
- Rosuvastatin/Valsartan
- Volunteers
- 1,000 people
- Sponsor
- LG Chem
Hypercholesterolemia, Hypertension
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.
- Trial name
- NCT02178098
- Testing
- ETC-1002
- Where
- 43 sites in United States
- Volunteers
- 143 people
- Sponsor
- Esperion Therapeutics, Inc.
Glaucoma
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.
- Trial name
- NCT02554214
- Testing
- Glafkos drainage device
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Rheon Medical SA
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.